Volume 5 | Issue 1 | DOI: https://doi.org/10.33696/Pharmacol.4.036
Off Label Use as an Indicator of Therapeutic Need in Pediatrics
- 1Italian Medicines Agency (AIFA), Via del Tritone, 181, 00187, Rome, Italy
- 2Department of Neurosciences, Psychology, Drug Research and Child Health, Section of Pharmacology and Toxicology, University of Florence, Viale G. Pieraccini, 6, 50139, Florence, Italy
Silvia Miriam Cammarata, email@example.com
Received Date: November 11, 2022
Accepted Date: November 21, 2022
Cammarata SM. Off Label Use as an Indicator of Therapeutic Need in Pediatrics. Arch Pharmacol Ther. 2023;5(1):1-4.
Copyright: © 2023 Cammarata SM. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Although NK cells are recognized as effector lymphocytes of the innate immune system, they also regulate the adaptive immune response by releasing inflammatory cytokines and developing immunological memory. Unlike other lymphocytes such as T or B cells, NK cells do not express rearrangeable, antigen-specific receptors.
Proton minibeam radiotherapy (pMBRT) is an external beam radiotherapy method with reduced side effects by taking advantage of spatial fractionation in the normal tissue. Due to scattering, the delivered small beams widen in the tissue ensuring a homogeneous dose distribution in the tumor. In this review, the physical and biological principles regarding dose distribution and healing effects are explained. In the last decade, several preclinical studies have been conducted addressing normal tissue sparing and tumor control in-vitro and in-vivo, using human skin tissue and mouse or rat models. The major results acquired in these studies are summarized. A further newly emerging therapy method is FLASH radiotherapy, i.e. the treatment using ultra-high dose rates. The possibility of combining these methods in proton minibeam FLASH therapy (pMB FLASH) is worked out. Additionally, technical feasibility and limitations will be discussed by looking at simulations as well as preclinical studies and also pointing out new ways of delivering the desired tumor dose, such as interlacing. We will also highlight the opportunities that emerge regarding high dose radiation, hypofractionation and the combination with immunotherapy.
Rituximab is a chimeric (20% rodent and 80% human) monoclonal antibody that binds to the CD20 antigen present on the cell surface and leads to depletion of mature B-cells [1,2]. It is the first approved monoclonal antibody to be used in the therapy of indolent B-cell non- Hodgkin’s lymphoma and chronic lymphocytic leukemia
During the last few decades, immunotherapy is considered to be an important approach to help our immune system to fight various kinds of diseases, such as tumor. Sometimes, it works very well for some types of cancers, for example: bladder cancer, colorectal cancer, breast cancer and lymphoma.
Acute Success and Long-term Follow-up of Catheter Ablation of Isthmus-dependent Atrial Flutter; A Comparison of 10 mm Tip Standard, 6 mm Tip Irrigated Radiofrequency, and Cryotherapy Catheters
Various catheter ablation technologies have evolved to improve the procedural success and safety of cavotricuspid isthmus (CTI) block. Numerous studies have compared the different energy types, catheter tip sizes, and energy settings.